Lithuania
2006: Reimbursement of anti-dementia drugs
The availability of medicines in general
Medicines in Lithuania are fully covered for children under 18, persons with group 1 disability and for hospital treatment. 50% of the price of medicines is covered for old-age pensioners, persons with group 2 disability and other persons entitled to a social insurance protection.
Finally, the Lithuanian system prescribes reimbursement levels for medicines for specific diseases on a special list for which reimbursement can be 50%, 80%, 90% or 100% depending on the disease.[1]
The availability of Alzheimer treatments
In Lithuania, only donepezil and memantine are part of the reimbursement system. People with an MMSE score between 20 and 0 can qualify for the reimbursement of donepezil. The same information for memantine was not available. There are no restrictions in Lithuania for the reimbursement of these treatments for people living alone or in nursing homes.
Alzheimer Europe has no information on whether there are special requirements in Lithuania as to which doctors can prescribe Alzheimer treatments.
Rivastigmine | Galantamine | Memantine |
||
Reimbursement | Yes | No | No | Yes |
Initial treatment decision | No information | N/A | N/A | No information |
Continuing treatment decision | No information | N/A | N/A | No information |
Required examinations | MMSE | N/A | N/A | No information |
MMSE limits | 20-0 | N/A | N/A | No information |
People living alone | No restrictions | N/A | N/A | No restrictions |
People in nursing homes | No restrictions | N/A | N/A | No restrictions |
[1] European Commission (2006): MISSOC – Mutual information system on social protection : Social protection in the Member States of the European Union, of the European Economic Area and in Switzerland : Comparative tables
Last Updated: Wednesday 15 July 2009